Genomic Health Reaches New 52-Week High (GHDX)

NEW YORK ( TheStreet) -- Genomic Health (Nasdaq: GHDX) hit a new 52-week high Tuesday as it is currently trading at $35.01, above its previous 52-week high of $35 with 140,090 shares traded as of 1:19 p.m. ET. Average volume has been 169,100 shares over the past 30 days.

Genomic Health has a market cap of $1.04 billion and is part of the health care sector and health services industry. Shares are up 36.1% year to date as of the close of trading on Friday.

Genomic Health, Inc., a molecular diagnostics company, engages in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. The company has a P/E ratio of 119.2, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

• Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Genomic Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. You can view the full Genomic Health Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.